StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$3.23+0.23 (+7.86%)

Close on Nov 18, 2026Market cap $335.02MP/E –Yield –

Larimar Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Larimar Therapeutics's free cash flow for the twelve months ending Jun 30, 2025 was -$92.59M. For fiscal 2025 it was -$113.29M. The highest annual figure on record is -$13.59M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.29M–
FY2024Dec 31, 2024-$71.28M–
FY2023Dec 31, 2023-$33.62M–
FY2022Dec 31, 2022-$27.67M–
FY2021Dec 31, 2021-$42.44M–
FY2020Dec 31, 2020-$42.26M–
FY2019Dec 31, 2019-$22.78M–
FY2018Dec 31, 2018-$51.60M–
FY2017Dec 31, 2017-$43.84M–
FY2016Dec 31, 2016-$52.64M–
FY2015Dec 31, 2015-$60.15M–
FY2014Dec 31, 2014-$28.30M–
FY2013Dec 31, 2013-$15.02M–
FY2012Dec 31, 2012-$13.59M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-$19.40M–
Q1 FY2025Mar 31, 2025-$26.59M–
Q4 FY2024Dec 31, 2024-$21.99M–
Q3 FY2024Sep 30, 2024-$24.61M–
Q4 FY2022Dec 31, 2022-$6.67M–
Q3 FY2022Sep 30, 2022-$5.88M–
Q4 FY2021Dec 31, 2021-$7.93M–
Q3 FY2021Sep 30, 2021-$12.49M–
Q4 FY2020Dec 31, 2020-$9.86M–
Q3 FY2020Sep 30, 2020-$11.23M–
Q2 FY2020Jun 30, 2020-$12.20M-451.1%
Q1 FY2020Mar 31, 2020-$8.98M–
Q4 FY2019Dec 31, 2019-$7.96M–
Q3 FY2019Sep 30, 2019-$5.82M–
Q2 FY2019Jun 30, 2019$3.48M–
Q1 FY2019Mar 31, 2019-$12.47M–
Q4 FY2018Dec 31, 2018-$11.85M–
Q3 FY2018Sep 30, 2018-$13.15M–
Q2 FY2018Jun 30, 2018-$13.33M–
Q1 FY2018Mar 31, 2018-$13.27M–
Q4 FY2017Dec 31, 2017-$9.86M–
Q3 FY2017Sep 30, 2017-$12.10M–
Q2 FY2017Jun 30, 2017-$10.19M–
Q1 FY2017Mar 31, 2017-$11.69M–
Q4 FY2016Dec 31, 2016-$8.67M–
Q3 FY2016Sep 30, 2016-$11.03M–

More Larimar Therapeutics figures

See a number that looks wrong?